What this study is
A multi-center, early feasibility study of using the Mechanical Tissue Resuscitation™ (MTR®) therapy system for removal of excess fluid in subjects who have had a portion of their skull removed to expose the dura/brain and require drainage for fluid removal.
What's being tested
- Mechanical Tissue Resuscitation™ (MTR®)
Intervention · DEVICE
Mechanical Tissue Resuscitation™ (MTR®) to drain excess fluid volume from the site of surgery in patients who have undergone a surgical procedure (craniotomy/craniectomy), or a procedure in which a portion of the skull has been repaired or replaced (cranioplasty), and who, as an integral part of their care would require placement of a Jackson Pratt drain (or equivalent).
Study details
- Sponsor
- Renovo Concepts, Inc.
- Conditions
- Clinical Need for Craniotomy or Craniectomy · Clinical Need for Cranioplasty
- Enrolling
- 11 people
- Starts
- 2024-11-01
- Est. completion
- 2026-12-31
- Design
- Open-label, single group
- Record
- View on ClinicalTrials.gov ↗
Who can join
Age 22 Years – 65 YearsSex ALLHealthy volunteers Not acceptedYou may qualify if
- Phase 1:
- Patient is willing and able to provide written informed consent or has an appointed legally authorized representative (LAR) who can provide consent on the patient's behalf.
- The patient's age is ≥ 22 and ≤ 65 years.
- The patient has a clinical need for a craniotomy, craniectomy, or cranioplasty and for which, as an integral part of their care, a Jackson Pratt (JP) drain or equivalent would be placed at the surgical site.
- The surgical case is classified as 'clean'. Phase 2:
- All Phase 1 criteria
- Patient has been diagnosed with a mild-to-moderate TBI with a GCS of 9 or above and has two reactive pupils. Phase 3:
- All Phase 1 criteria
- Patient has suffered an acute, severe TBI with a GCS of 7-8 and has two reactive pupils.
You can't join if
- Phase 1:
- Patient has suffered an acute, severe traumatic brain injury, defined as less than 7 days since injury with GCS of less than 13.
- Patient is pregnant or lactating.
- Patient's BMI > 45
- Patient is participating in another clinical investigation.
- Patient's anticipated survival is < 48 hours.
- Patient is incarcerated at time of hospital admission.
- Patient has a coincidental infection.
- Patient has thrombocytopenia (platelet count < 150,000/µL).
- Patient has an International Normalized Ratio (INR) > 1.5.
- Patient is a known active opioid abuser at the time of surgery.
- Patient is a known active alcohol abuser at the time of surgery.
- Active bleeding at the site of surgery prior to placement of the device. Phases 2 and 3:
Sign in and we'll check these against your records.Full criteria on ClinicalTrials.gov ↗
Loading treatment details…
Study locations (3)
3 openUniversity at Buffalo Neurosurgery
Buffalo, New York, United States
RecruitingAtrium Health Wake Forest Baptist
Winston-Salem, North Carolina, United States
RecruitingWest Virginia University
Morgantown, West Virginia, United States
Recruiting
Study team
Sponsor
Renovo Concepts, Inc.
Study ID 2023-01
Frequently asked questions
The sponsor hasn't published answers to common questions for this trial.